Last reviewed · How we verify
Pred
Pred is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors.
Pred is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.
At a glance
| Generic name | Pred |
|---|---|
| Also known as | Prednisone |
| Sponsor | Qilu Hospital of Shandong University |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Pred (prednisolone or prednisone) is a systemic corticosteroid that acts as a glucocorticoid receptor agonist, reducing the production of pro-inflammatory cytokines and suppressing T-cell and B-cell activity. It is used to manage a wide range of inflammatory and autoimmune conditions by broadly dampening immune-mediated inflammation.
Approved indications
- Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)
- Allergic reactions and asthma exacerbations
- Adrenal insufficiency
- Certain hematologic malignancies and lymphomas
Common side effects
- Hyperglycemia
- Hypertension
- Osteoporosis
- Immunosuppression / increased infection risk
- Insomnia and mood changes
- Gastrointestinal upset
- Weight gain
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement (NA)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pred CI brief — competitive landscape report
- Pred updates RSS · CI watch RSS
- Qilu Hospital of Shandong University portfolio CI